If you wanted to minimize the real-life effects of misconduct, you might note that some of the retractions we cover are in tiny obscure journals hardly anyone reads. But a new meta-analysis and editorial in JAMA today suggests — as a study by Grant Steen did a few years ago — that the risk of patient harm due to scientific misconduct is not just theoretical.
As the editorialists note, hydroxyethyl starches (HES) are “synthetic fluid products used commonly in clinical practice worldwide:”
Synthetic colloids received market approval in the 1960s without evaluation of their efficacy and safety in large phase 3 clinical trials. Subsequent studies reported mixed evidence on their benefits and harms.
There has been controversy over the use of HES for decades, with the most recent high-level review showing “no significant mortality increase.” But one of the reasons for that review — by the prestigious Cochrane Collaboration — was to see if the dozens of now-retracted studies by Joachim Boldt Continue reading Does scientific misconduct cause patient harm? The case of Joachim Boldt
